patent.fyi
Applications  /  US 2026/0355353
United States Patent Application Publication

US 2026/0355353 A1

Published
Nov 12, 2026
Filed
Mar 1, 2024
Earliest date on the face
Mar 2, 2023
Classification
A61K 48/005
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Direct IL-2 protein delivery

What ifWhat if the arrangement supplies purified IL-2 protein as the first component?
Claim language“a first recombinant polynucleotide encoding an Interleukin (IL)-2 polypeptide”

Purified IL-2 binds IL-2 receptors on responsive T cells and natural killer cells. The second polynucleotide supplies IL-12 through expression in recipient cells.

1.1Direct IL-12 protein delivery

What ifWhat if the arrangement supplies purified IL-12 protein as the second component?
Claim language“a second recombinant polynucleotide encoding an IL-12 polypeptide”

The second component contains the assembled IL-12 p35 and p40 protein subunits. The heterodimer binds IL-12 receptors on responsive immune cells, while the first polynucleotide supplies IL-2 through cellular expression.

1.1IL-15 as the encoded cytokine

What ifWhat if the first polynucleotide encodes IL-15?
Claim language“an Interleukin (IL)-2 polypeptide”

Cells translate the first polynucleotide into IL-15. IL-15 presented by IL-15 receptor alpha activates the shared receptor beta and common gamma chains on responsive lymphocytes.

1.1IL-18 as the encoded cytokine

What ifWhat if the second polynucleotide encodes secreted mature IL-18?
Claim language“an IL-12 polypeptide”

A cleavable secretion signal directs mature IL-18 through the cellular secretory pathway. Extracellular IL-18 activates its own receptor and promotes interferon-gamma production in activated T cells and natural killer cells.

1.1One transcript for both cytokines

What ifWhat if a single recombinant RNA molecule encodes both cytokines?
Claim language“a second recombinant polynucleotide”

The RNA contains an upstream IL-2 coding region and a downstream single-chain IL-12 coding region. An internal ribosome entry site initiates translation of the downstream region on the same transcript.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Paired controls for veterinary assay training

A veterinary laboratory training kit contains recombinant polynucleotides encoding bovine interleukin-2 and bovine interleukin-12. The kit places the two templates in separate wells and includes a third well containing both templates. Trainees run target-specific amplification assays and compare the detected targets with the supplied well map.

Component substitution

Messenger RNA replaces one DNA template

A recombinant messenger RNA encoding interleukin-2 replaces the interleukin-2 DNA template in a two-component analytical control. The second component remains a recombinant DNA template encoding interleukin-12, and both components occupy the same control vial. The assay splits an aliquot into paired reactions with and without reverse transcriptase to distinguish the RNA-derived signal from the DNA signal.

Parameter or scale variation

Copy ratio panel for duplex assays

A control panel contains recombinant interleukin-2 and interleukin-12 DNA templates mixed at copy-number ratios of 1:9, 1:1, and 9:1. Each mixture contains 10,000 total template copies per microliter in the same buffer. A duplex digital amplification assay counts each target in a separate fluorescence channel and reports the measured ratio for each mixture.

Combination with existing systems

Paired controls in a microfluidic cartridge

A microfluidic amplification cartridge includes a control reservoir containing both recombinant DNA templates. The cartridge meters the control mixture into two reaction chambers, each containing primers and a probe for one cytokine target. An optical reader records the signals from both control chambers before reporting results from the sample chambers.

Automated or data-driven variant

Automated verification of both coding sequences

Two indexed sequencing libraries contain the recombinant interleukin-2 and interleukin-12 polynucleotides, with one index assigned to each component. Software assigns reads by index, aligns them to the corresponding reference sequence, and calculates coverage across each coding region. The report lists sequence differences, positions with insufficient coverage, and reads assigned to the other component's reference.

Automated dispensing of paired assay controls

An automated liquid handler draws the recombinant interleukin-2 and interleukin-12 polynucleotides from separate source wells. A plate map specifies wells for each single-target control, the mixed control, and a buffer-only control. The instrument dispenses each source with a fresh tip and records source identifiers and dispense volumes for each destination well.

Specific version of a part

Two circular DNA plasmids

One plasmid contains an IL-2 expression cassette and the other contains a single-chain IL-12 expression cassette. Each cassette contains a mammalian promoter and a downstream cleavage and polyadenylation signal.

IL-12 with independently translated subunits

The first RNA encodes IL-2. The second RNA carries separate coding regions for IL-12 p35 and p40, with an internal ribosome entry site for the downstream subunit. Each subunit has a secretion signal, and the two subunits assemble into heterodimeric IL-12.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2005/0025745 A1
Published
Feb 3, 2005
Filed
Feb 23, 2004
Document BUS 2007/0207943 A1
Published
Sep 6, 2007
Filed
Jan 22, 2007
Class
A61K 38/02
Claim 1
Document A
Document B
1.1a first recombinant polynucleotide encoding an Interleukin (IL)-2 polypeptide and a second recombinant polynucleotide encoding an IL-12 polypeptide.
(4) The method as described above in any one of (1) to (3), wherein the DNA is selected from the group consisting of: (a) DNA coding for a protein having an antitumor activity, and (b) DNA coding for a protein having an activity of converting a precursor of an antitumor substance into the antitumor substance; (5) The method as described above in (4), wherein the protein having an antitumor activity is interleukin-2;
A · US 2005/0025745 A1 · ¶ 19
The present invention also relates to vectors containing the IL-21 and IL-22 polynucleotides, host cells, and the production of polypeptides by recombinant techniques.
B · US 2007/0207943 A1 · ¶ 186

An empty cell means only that no passage was reproduced there.

Statements in these documents
However, these bacteria have pathogenicity in humans and are thus not always safe gene delivery vectors in gene therapy of solid tumors.
A · US 2005/0025745 A1 · ¶ 7
The present invention relates to anaerobic bacteria belonging to the genus Bifidobacterium useful for gene therapy of solid tumors, a pharmaceutical composition containing the same, a method of delivering a gene and a method of treating solid tumors by use of the same.
A · US 2005/0025745 A1 · ¶ 2
Thus, there is a need for polypeptides that function as immunoregulatory molecules and, thereby, modulate the transfer of an extracellular signal ultimately to the nucleus of the cell, since disturbances of such regulation may be involved in disorders relating to cellular activation, hemostasis, angiogenesis, tumor metastasis, cellular migration and ovulation, as well as neurogenesis.
B · US 2007/0207943 A1 · ¶ 7
Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders.
B · US 2007/0207943 A1 · ¶ 8
Cite aspatent.fyi, US 2026/0355353 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355353/, SHA-256 2cd2f5dadd66f136957abf05d78c355bb130d871bbf84005baed816df5da81d9
First published
Permanent addresshttps://patent.fyi/US20260355353/
Content fingerprint (SHA-256)2cd2f5dadd66f136957abf05d78c355bb130d871bbf84005baed816df5da81d9
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi